Cempra Company Profile (NASDAQ:CEMP)

About Cempra (NASDAQ:CEMP)

Cempra logoCempra, Inc. is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus, coagulase negative staphylococci and other gram-positive bacteria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:CEMP
  • CUSIP: 15130J10
  • Web: www.cempra.com
Capitalization:
  • Market Cap: $202.14 million
  • Outstanding Shares: 52,503,000
Average Prices:
  • 50 Day Moving Avg: $3.87
  • 200 Day Moving Avg: $4.43
  • 52 Week Range: $2.55 - $26.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $20.21 million
  • Price / Sales: 10.00
  • Book Value: $3.10 per share
  • Price / Book: 1.24
Profitability:
  • EBIDTA: ($103,090,000.00)
  • Net Margins: -678.72%
  • Return on Equity: -59.94%
  • Return on Assets: -47.76%
Debt:
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 10.19%
  • Quick Ratio: 10.19%
Misc:
  • Average Volume: 1.23 million shs.
  • Beta: 0.95
  • Short Ratio: 1.87
 

Frequently Asked Questions for Cempra (NASDAQ:CEMP)

What is Cempra's stock symbol?

Cempra trades on the NASDAQ under the ticker symbol "CEMP."

How were Cempra's earnings last quarter?

Cempra Inc (NASDAQ:CEMP) released its quarterly earnings results on Friday, April, 28th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.16. The company earned $4.87 million during the quarter, compared to the consensus estimate of $3.55 million. Cempra had a negative net margin of 678.72% and a negative return on equity of 59.94%. During the same period in the prior year, the firm earned ($0.61) earnings per share. View Cempra's Earnings History.

When will Cempra make its next earnings announcement?

Cempra is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Cempra.

Where is Cempra's stock going? Where will Cempra's stock price be in 2017?

15 equities research analysts have issued 1 year price targets for Cempra's stock. Their forecasts range from $2.50 to $32.00. On average, they expect Cempra's stock price to reach $12.30 in the next year. View Analyst Ratings for Cempra.

What are analysts saying about Cempra stock?

Here are some recent quotes from research analysts about Cempra stock:

  • 1. According to Zacks Investment Research, "Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. " (5/3/2017)
  • 2. Robert W. Baird analysts commented, "Cempra announced this morning that the MAA filed in Europe has been withdrawn. We believe it is likely due to the same safety concerns brought up by the FDA. At this point, the path forward for solithromycin appears to us to be a dead end and any additional expenditures will only diminish the company's otherwise attractive cash position. We reiterate our Underperform rating." (3/28/2017)
  • 3. Stifel Nicolaus analysts commented, "Incremental solithromycin updates provided on management's 4Q16 earnings announcement/call now meaningfully increase the likelihood this asset ' in its current formulation ' is unlikely to represent a source of any future value. In addition to FDA seemingly reiterating its stance on wanting 9,000 patients of additional CABP data to assuage hepatotoxicity concerns, EMA is now requesting additional data and management's commentary would suggest any regulatory path forward here is likely to prove challenging. Solithromycin also failed to achieve non-inferiority within the primary cohort of the P3 SOLITAIRE-U trial (gonorrhea), the NASH study has been suspended, and the COPD study has been closed. We've removed all solithromycin-related value (ex-Japan) from our model and believe any viable commercialization argument for Taksta is likely to hinge on YE17 P2 prosthetic joint infection data. Target decreased to $4 (previously $8)." (3/1/2017)

Who are some of Cempra's key competitors?

Who owns Cempra stock?

Cempra's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (9.99%), Vanguard Group Inc. (5.49%), Renaissance Technologies LLC (3.20%), Bogle Investment Management L P DE (1.35%), South Dakota Investment Council (1.35%) and C WorldWide Group Holding A S (1.25%). Company insiders that own Cempra stock include David Moore, David N Gill, David W Oldach, Dov A Md Goldstein and Garheng Kong. View Institutional Ownership Trends for Cempra.

Who sold Cempra stock? Who is selling Cempra stock?

Cempra's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, C WorldWide Group Holding A S, KCG Holdings Inc., Tudor Investment Corp ET AL, JPMorgan Chase & Co., Schwab Charles Investment Management Inc. and Credit Suisse AG. View Insider Buying and Selling for Cempra.

Who bought Cempra stock? Who is buying Cempra stock?

Cempra's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bogle Investment Management L P DE, Bellevue Group AG, Acadian Asset Management LLC, TIAA CREF Investment Management LLC, Morgan Stanley, South Dakota Investment Council and Oxford Asset Management. Company insiders that have bought Cempra stock in the last two years include David Moore, David N Gill and Garheng Kong. View Insider Buying and Selling for Cempra.

How do I buy Cempra stock?

Shares of Cempra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cempra stock cost?

One share of Cempra stock can currently be purchased for approximately $3.85.

Analyst Ratings

Consensus Ratings for Cempra (NASDAQ:CEMP) (?)
Ratings Breakdown: 3 Sell Ratings, 9 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $12.30 (219.39% upside)

Analysts' Ratings History for Cempra (NASDAQ:CEMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Jefferies Group LLCReiterated RatingHold$3.00LowView Rating Details
3/29/2017GabelliDowngradeHold -> SellHighView Rating Details
3/28/2017Robert W. BairdReiterated RatingUnderperformMediumView Rating Details
3/1/2017Stifel NicolausReiterated RatingHold$4.00N/AView Rating Details
2/27/2017Roth CapitalUpgradeNeutral -> Buy$8.00 -> $2.50N/AView Rating Details
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
1/2/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
1/2/2017Cantor FitzgeraldSet Price TargetBuy$28.00N/AView Rating Details
12/30/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
12/30/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$5.00 -> $5.00N/AView Rating Details
12/29/2016WBB SecuritiesDowngradeBuy -> Hold$40.00 -> $4.00N/AView Rating Details
12/29/2016S&P Equity ResearchBoost Price Target$2.65 -> $3.15N/AView Rating Details
12/29/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
12/20/2016SunTrust Banks, Inc.DowngradeBuy -> Sell$18.00 -> $5.00N/AView Rating Details
11/8/2016Royal Bank of CanadaReiterated RatingBuy$27.50N/AView Rating Details
11/2/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformN/AView Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Cempra (NASDAQ:CEMP)
Earnings by Quarter for Cempra (NASDAQ:CEMP)
Earnings History by Quarter for Cempra (NASDAQ:CEMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017        
4/28/2017Q1 2017($0.53)($0.37)$3.55 million$4.87 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.57)($0.60)$4.19 million$7.95 millionViewListenView Earnings Details
10/27/2016Q3($0.64)($0.62)$3.90 million$4.00 millionViewListenView Earnings Details
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/1/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.41)($0.57)$4.60 million$5.05 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.46)($0.46)$3.50 million$2.47 millionViewListenView Earnings Details
10/29/2014Q314($0.59)($0.34)$1.59 million$7.77 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cempra (NASDAQ:CEMP)
2017 EPS Consensus Estimate: ($1.23)
2018 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.55)($0.48)($0.51)
Q2 20173($0.39)($0.26)($0.32)
Q3 20173($0.24)($0.18)($0.22)
Q4 20173($0.20)($0.16)($0.18)
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.20)($0.20)($0.20)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cempra (NASDAQ:CEMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cempra (NASDAQ:CEMP)
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 79.92%
Insider Trades by Quarter for Cempra (NASDAQ:CEMP)
Institutional Ownership by Quarter for Cempra (NASDAQ:CEMP)
Insider Trades by Quarter for Cempra (NASDAQ:CEMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/8/2017Dov A Md GoldsteinDirectorSell150,000$3.55$532,500.00View SEC Filing  
1/13/2017Dov A Md GoldsteinDirectorSell105,460$3.40$358,564.00View SEC Filing  
1/6/2017Dov A Md GoldsteinDirectorSell937,600$3.41$3,197,216.00View SEC Filing  
1/3/2017David N GillDirectorBuy5,000$2.94$14,700.00View SEC Filing  
3/1/2016David MooreInsiderBuy500$16.18$8,090.00View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.52View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.00View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.00View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.90View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cempra (NASDAQ:CEMP)
Latest Headlines for Cempra (NASDAQ:CEMP)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Cempra, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 3:58 PM
americanbankingnews.com logoCempra Inc (CEMP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 12 at 11:21 AM
americanbankingnews.com logo$3.72 Million in Sales Expected for Cempra Inc (CEMP) This Quarter
www.americanbankingnews.com - May 11 at 9:34 AM
globenewswire.com logoCempra Presents Data on Ophthalmic Solithromycin at ARVO - GlobeNewswire (press release)
globenewswire.com - May 10 at 8:30 AM
finance.yahoo.com logoCempra Presents Data on Ophthalmic Solithromycin at ARVO
finance.yahoo.com - May 10 at 8:30 AM
americanbankingnews.com logoCempra Inc (CEMP) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - May 10 at 12:10 AM
americanbankingnews.com logoCempra (CEMP) Receiving Somewhat Positive News Coverage, Analysis Finds
www.americanbankingnews.com - May 4 at 6:04 PM
finance.yahoo.com logoETFs with exposure to Cempra, Inc. : May 4, 2017
finance.yahoo.com - May 4 at 4:21 PM
americanbankingnews.com logoCempra Inc (CEMP) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 4 at 12:58 AM
finance.yahoo.com logoCempra loses executive, but eyes FDA feedback
finance.yahoo.com - May 3 at 4:14 PM
finance.yahoo.com logoCempra, Inc. :CEMP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 4:14 PM
americanbankingnews.com logoGabelli Comments on Cempra Inc's FY2017 Earnings (CEMP)
www.americanbankingnews.com - May 3 at 1:45 PM
americanbankingnews.com logoCempra Inc (CEMP) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 11:14 PM
americanbankingnews.com logoCempra (CEMP) Receives Daily News Impact Rating of 0.40
www.americanbankingnews.com - May 1 at 2:08 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Cempra and PhaseRx - Yahoo Finance
finance.yahoo.com - May 1 at 8:47 AM
finance.yahoo.com logoCempra Reports First Quarter 2017 Financial Results and Provides Corporate Update - Yahoo Finance
finance.yahoo.com - April 29 at 6:34 AM
nasdaq.com logoEarnings Reaction History: Cempra Inc, 66.7% Follow-Through Indicator, 7.9% Sensitive - Nasdaq
www.nasdaq.com - April 29 at 6:34 AM
americanbankingnews.com logoCempra Inc (CEMP) Issues Quarterly Earnings Results
www.americanbankingnews.com - April 29 at 1:28 AM
americanbankingnews.com logoCempra Inc (CEMP) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - April 29 at 1:27 AM
americanbankingnews.com logoCempra (CEMP) Receiving Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 11:08 PM
finance.yahoo.com logoEdited Transcript of CEMP earnings conference call or presentation 28-Apr-17 12:45pm GMT
finance.yahoo.com - April 28 at 10:12 PM
seekingalpha.com logoCempra, Inc. (CEMP)
seekingalpha.com - April 28 at 5:12 PM
finance.yahoo.com logoCempra Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - April 28 at 5:12 PM
marketbeat.com logoCempra reports 1Q loss
marketbeat.com - April 28 at 7:43 AM
americanbankingnews.com logoCempra (CEMP) Receives Coverage Optimism Score of -0.11
www.americanbankingnews.com - April 25 at 1:09 PM
americanbankingnews.com logoCempra (CEMP) Getting Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 21 at 1:19 PM
americanbankingnews.com logoCempra Inc (CEMP) Expected to Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - April 19 at 7:54 AM
americanbankingnews.com logoCempra (CEMP) Earns Daily Coverage Optimism Rating of 0.03
www.americanbankingnews.com - April 18 at 2:12 PM
americanbankingnews.com logoCempra Inc (CEMP) Short Interest Update
www.americanbankingnews.com - April 17 at 4:00 PM
americanbankingnews.com logoCempra Inc (CEMP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 17 at 11:34 AM
americanbankingnews.com logoCempra Inc (CEMP) Downgraded to Buy at Vetr Inc.
www.americanbankingnews.com - April 16 at 7:26 AM
globenewswire.com logoCempra to Report First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - April 13 at 7:56 AM
finance.yahoo.com logoCempra to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 13 at 7:55 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for Cempra Inc's FY2020 Earnings (CEMP)
www.americanbankingnews.com - March 31 at 3:01 PM
americanbankingnews.com logoCempra Inc (CEMP) Downgraded by Vetr Inc. to Sell
www.americanbankingnews.com - March 31 at 12:29 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Cempra Inc's FY2021 Earnings (CEMP)
www.americanbankingnews.com - March 30 at 2:19 PM
americanbankingnews.com logoCempra Inc (CEMP) Cut to Sell at Gabelli
www.americanbankingnews.com - March 29 at 4:37 PM
globenewswire.com logoCempra Withdraws Solithromycin Marketing Authorization Application in Europe - GlobeNewswire (press release)
globenewswire.com - March 29 at 12:23 PM
globenewswire.com logoCempra to Present at the 16th Annual Needham & Company Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 29 at 12:23 PM
americanbankingnews.com logoCempra's (CEMP) "Underperform" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - March 28 at 1:10 PM
streetinsider.com logoCempra (CEMP) Withdraws MAA for Solithromycin in Europe
www.streetinsider.com - March 28 at 12:47 PM
us.rd.yahoo.com logoCempra Withdraws Solithromycin Marketing Authorization Application in Europe
us.rd.yahoo.com - March 28 at 12:47 PM
thestreet.com logoBiotech Premarket Movers: Cempra, Tesaro, Editas
us.rd.yahoo.com - March 28 at 12:47 PM
bizjournals.com logoFor Chapel Hill's Cempra, no European launch for now
www.bizjournals.com - March 28 at 12:47 PM
americanbankingnews.com logoVetr Inc. Downgrades Cempra Inc (CEMP) to Sell
www.americanbankingnews.com - March 28 at 12:37 AM
seekingalpha.com logoCempra: Why This Small-Cap Biotech May Soar Soon
seekingalpha.com - March 27 at 12:42 PM
americanbankingnews.com logoVetr Inc. Downgrades Cempra Inc (CEMP) to Strong Sell
www.americanbankingnews.com - March 26 at 10:34 AM
americanbankingnews.com logoCempra Inc (CEMP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 1:37 PM
americanbankingnews.com logoCempra Inc (CEMP) Stock Rating Lowered by Vetr Inc.
www.americanbankingnews.com - March 21 at 12:22 AM
us.rd.yahoo.com logoCempra Retains Morgan Stanley to Lead Review of Strategic Business Options
us.rd.yahoo.com - March 13 at 12:46 PM

Social

Chart

Cempra (CEMP) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff